Edition:
United Kingdom

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

66.78USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$66.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
40,345
52-wk High
$76.29
52-wk Low
$22.30

Chart for

About

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone... (more)

Overall

Beta: --
Market Cap(Mil.): $1,304.09
Shares Outstanding(Mil.): 36.37
Dividend: --
Yield (%): --

Financials

  ASND.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -3.50 -- --
ROI: -83.31 2.00 14.38
ROE: -83.31 3.49 16.08

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP

08 May 2018

BRIEF-Ascendis Pharma Reports Full Year 2017 Financial Results

* ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS

28 Mar 2018

BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

22 Feb 2018

BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS

* ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

20 Feb 2018

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

03 Jan 2018

Competitors

Earnings vs. Estimates